Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial

Vanita Noronha; Vijay Patil; Nandini Menon; Minit Shah; Anuradha Chougule; Zoya Peelay; Kumar Prabhash

doi:10.1001/jamaoncol.2024.0584

Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial

JAMA Oncol. 2024 Apr 25:e240584. doi: 10.1001/jamaoncol.2024.0584. Online ahead of print.

Authors

Vanita Noronha^{1

2}, Vijay Patil^{1

2}, Nandini Menon^{1

2}, Minit Shah^{1

2}, Anuradha Chougule^{1

2}, Zoya Peelay^{1

2}, Kumar Prabhash^{1

2}

Affiliations

¹ Solid Tumor Unit, Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Mumbai, India.
² Homi Bhabha National Institute, Mumbai, India.

PMID: 38662354
PMCID: PMC11046413 (available on 2025-04-25)
DOI: 10.1001/jamaoncol.2024.0584

No abstract available

Plain language summary

This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer.